1 Hagner N,Joerger M.Cancer chemotherapy:targeting folic acid synthesis[J].Cancer Manag Res,2010,19(5):293-301.
2 吴杨佳子,高玉艳,张艳桥.精氨酸酶在结直肠癌中的研究进展[J].实用肿瘤学杂志,2013,27(5):460-462.
3 Van CE,Oliveirea J.ESMO Guidelines Working Group.Advanced colorectal cancer:ESMO clinical recommendations for diagnosis,treatment and follow-up[J].Ann Oncol,2009,20(4):61-65.
4 Barni S,Ghidini A,Coinu A,et al.A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer[J].Anticancer Drugs,2014,25(10):1122-1128.
5 Liu Y,Wu W,Hong W,et al.Raltitrexed-based chemotherapy for advanced colorectal cancer[J].Clin Res Hepatol Gastroenterol,2014,38(2):219-225.
6 Bozkurt O,Karaca H,Ciltas A,et al.Efficacy and safety of raltitrexed combinations with uracil-tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients:a multicenter study of anatolian society of medical oncology(ASMO)[J].Asian Pac J Cancer Prev,2014,15(4):1845-1849.
7 王佳蕾,李进,刘天舒,等.雷替曲塞或5-FU/CF联合奥沙利铂治疗局部晚期或复发转移性结直肠癌多中心、随机、对照Ⅲ期临床试验[C].北京:第十届全国临床肿瘤学大会暨2007年CSCO学术年会中国临床肿瘤学教育专辑,2007:335-340.
8 Kim GP,Sargent DJ,Mahoney MR,et al.Phase III noninferiority trial comparing irinotecan with oxaliplatin,fluorouracil,and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil:N9841[J].J Clin Oncol,2009,27(17):2848-2854.
9 Shen J,Wang H,Wei J,et al.Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer[J].Int J Cancer,2012,131(6):938-945.
10 孙静,胜照杰.雷替曲塞联合多西他赛治疗进展期胃癌的临床观察[J].现代中西医结合杂志,2013,22(22):2435-2438.
11 Wei J,Costa C,Ding Y,et al.mRNA expression of BRCA1,PIAS1,and PIAS4 and survival after second-line docetaxel in advanced gastric cancer[J].J Natl Cancer Inst,2011,103(20):1552-1556.
12 Wesolowski R,Lee C,Kim R.Is there a role for second-line chemotherapy in advanced gastric cancer?[J].Lancet Oncol,2009,10(9):903-912.
13 岳顺,张大红,周磊磊.雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J].肿瘤防治研究,2014,41(2):160-162.
14 王咏梅,王革芳,吴成利,等.雷替曲塞等化疗药物低剂量动脉灌注治疗胃癌术后并发恶性肠梗阻[J].实用临床医药杂志,2012,16(13):18-22.
15 Cowley MJ,Chang DK,Pajic M,et al.Understanding pancreatic cancer genomes[J].J Hepatobiliary Pancreat Sci,2013,20(6):549-556.
16 Kedia P,Gaidhane M,Kahaleh M.Technical Advances in Endoscopic Ultrasound(EUS)-Guided Tissue Acquisition for Pancreatic Cancers:How Can We Get the Best Results with EUS-Guided Fine Needle Aspiration?[J].Clin Endosc,2013,46(5):552-562.
17 Francois E,Hebbar M,Bennouna J,et al.A phase II trial of raltitrexed(Tomudex)in advanced pancreatic and biliary carcinoma[J].Oncology,2005,68(4-6):299-305.
18 Arends JJ,Sleeboom HP,Leys MB,et al.A phase II study ofraltitrexed and gemcitabine in patients with advanced pancreatic carcinoma[J].Br J Cancer,2005,92(3):445-448.
19 Reni M,Pasetto L,Aprile G,et al.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer[J].Br J Cancer,2006,94(6):785-791.
20 孙静,胜照杰,郭君兰.雷替曲塞联合顺铂治疗进展期食管癌疗效观察[J].现代中西医结合杂志,2014,23(27):2989-2997.
21 夏铀铀,王磊,宋大安,等.放疗联合雷替曲塞奥沙利铂同步治疗晚期食管癌的Ⅱ期临床研究[J].中国肿瘤床,2014,41(11):716-719.
22 Bottomley A,Gaafar R,Manegold C,et al.Short-term treatment-related symptoms and quality of life:results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma:an EORTC Lung-Cancer Group and National Cancer Institute,Canada,Intergroup Study [J].J Clin Oncol,2006,24(9):1435-1442.
23 迟洪亮.奈达铂联合雷替曲塞治疗晚期喉咽癌17例分析[J].中国医药指南,2014,12(19):199-200.
24 Galetta D,Giotta F,Rosati G,et al.Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cellcarcinoma[J].Anticancer Res,2005,25(7):4445-4449.
25 刘佳,白玉贤.晚期原发性肝癌的全身化疗及靶向治疗[J].实用肿瘤学杂志,2013,27(1):88-92.
26 梁君,陈元龙,潘辉娟,等.以雷替曲塞为基础经动脉灌注化疗的安全性和有效性分析[J].影像诊断与介入放射学,2013,22(6):436-438
27 韩啸,张竞竞,王洪亚,等.雷替曲塞或氟尿嘧啶联合吉西他滨治疗晚期乳腺癌的疗效比较[J].蚌埠医学院报,2013,38(8):946-950.
28 Li XY,Liu L,Xie XM,et al.The role ofraltitrexed/cisplatin with concurrent radiation therapyin treating advanced cervical cancer[J].Eur Rev Med Pharmacol Sci,2014,18(22):3491-3496.